[6-K] Abivax SA American Current Report (Foreign Issuer)

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Analyzing...

07/22/2025 - 05:17 PM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Abivax S.A.

NASDAQ:ABVX

ABVX Rankings

#4521 Ranked by Market Cap

N/A Ranked by Dividends

ABVX Latest News

Jul 22, 2025

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

Jun 11, 2025

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Jun 2, 2025

Abivax Presents First Quarter 2025 Financial Results

Apr 29, 2025

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Apr 22, 2025

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

ABVX Stock Data

Market Cap 560.46M

Float 63.42M

Institutions Ownership 47.53%

Short Percent 1.95%

Industry Biotechnology

Sector Healthcare

Website Link

Country France

City Paris